Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib

1. november 2011 opdateret af: Radboud University Medical Center

Evaluation of Cognitive Function of Patients Treated With Sunitinib or Sorafenib

Patients with advanced kidney cancer or GIST (Gastro Intestinal Stromal Tumor: this is a tumor of the intestines) may be eligible for treatment with one of the following drugs: sunitinib (Sutent ®) or sorafenib (Nexavar ®). These drugs inhibit blood vessel formation in cancer cells. These cancer cells are hampered in their growth. To enlarge the investigators knowledge on the effects and side effects of these two medicines, in the University Medical Center St. Radboud lot of research is done. This study is a part of that.

Patients receiving sunitinib or sorafenib tell sometimes that they feel that they are less able to concentrate, that their memory is not working properly or that they are less able to imagine a solution to a complex problem . Perhaps you recognize these symptoms as well. In how many of the patients this occurs, how severe the symptoms are and how it is caused, is still unknown.

The goal of this research is to examine how memory, concentration and knowledge processing works in patients using sorafenib or sunitinib. With the research the investigators hope to get answers to the following questions:

  1. How common are problems with memory, concentration and processing of knowledge in patients receiving the drug sunitinib or sorafenib?
  2. What are the problems of memory, concentration and processing of knowledge in the use of sunitinib or sorafenib?
  3. What could be the cause of the problems that patients experience from memory, concentration and processing of knowledge in the use of sunitinib or sorafenib?
  4. Is there a link between problems with memory, concentration and processing of knowledge and also experiences of fatigue or mood of a patient?

Studieoversigt

Status

Afsluttet

Detaljeret beskrivelse

In this study we will focus on subjective and objective cognitive dysfunctioning in patients with metastatic cancer, treated with sunitinib or sorafenib. In our own clinical practice a substantial part of our patients that are treated with targeted therapies directed against VEGF, mention that they have problems with concentrating and that their memory function is decreased. Relatives sometimes point out that the behaviour of the patient is slightly different than before starting the VEGF (Vascular Endothelial Growth Factor) inhibition. Pre-clinical studies show that VEGF influences growth and recovery of neurons.

Undersøgelsestype

Observationel

Tilmelding (Forventet)

50

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Gelderland
      • Nijmegen, Gelderland, Holland, 6500 HB
        • University Medical Centre Nijmegen

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients with mRCC are asked by their own physician.

Beskrivelse

Inclusion Criteria:

  • Patients:
  • patients with metastatic renal cell cancer or GIST who are on treatment with Sunitinib or Sorafenib for ≥ 8 weeks
  • Karnofsky score > 70%
  • age > 18 year.
  • written informed consent for study

Patient controls selection

  • patients with metastatic renal cell cancer or GIST who aren't treated yet (only interferon alfa or interleukine 2 treatment is allowed when > 12 months ago.
  • Karnofsky score > 70%
  • age > 18 year.
  • written informed consent for study

Exclusion Criteria:

  • Patients:
  • contra-indications for treatment with Sunitinib or Sorafenib
  • patients who do not speak or write the Dutch language adequately
  • known brain metastasis
  • use of psychiatric or anti-epileptic medication
  • known cognitive disorders unrelated to diagnosis or medication use
  • radiotherapy on the brain at any time in the past
  • systemic chemotherapy
  • in the last 12 months interferon alfa or interleukin-2 treatment
  • operation in the last 3 months
  • Stroke/TIA (transient ischaemic attack)

Patient controls section:

  • patients who do not speak or write the Dutch language adequately
  • known brain metastasis
  • use of psychiatric or anti-epileptic medication
  • known cognitive disorders unrelated to diagnosis or medication use
  • radiotherapy on the brain at any time in the past
  • systemic chemotherapy
  • in the last 12 months interferon alfa or interleukin-2 treatment
  • operation in the last 3 months
  • stroke/TIA (transient ischaemic attack)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
metastatic Renal Cell Carcinoma without treatment
patients with metastasized RCC who did not receive treatment
mRCC with treatment

patients with metastastic renal cell cancer or GIST who are on treatment with Sunitinib or Sorafenib for

≥ 8 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. juli 2009

Primær færdiggørelse (Faktiske)

1. april 2011

Studieafslutning (Faktiske)

1. april 2011

Datoer for studieregistrering

Først indsendt

22. november 2010

Først indsendt, der opfyldte QC-kriterier

22. november 2010

Først opslået (Skøn)

23. november 2010

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

2. november 2011

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. november 2011

Sidst verificeret

1. oktober 2011

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner